Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    VolitionRx

    MCap

    USD63m

    Last close

    USD0.68

    ▲ 0.10 (16.35%)

    Creotech Instruments

    MCap

    PLN346m

    Last close

    PLN174.00

    ▲ 23.50 (15.61%)

    Creo Medical

    MCap

    GBP80m

    Last close

    GBP0.19

    ▲ 2.25 (13.24%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Actinogen Medical – executive interview

Actinogen Medical – executive interview

Actinogen Medical — 5 videos in collection

More on this equity

Actinogen Medical is a biotechnology company developing its lead compound, Xanamem, as a revolutionary new therapy for Alzheimer’s disease, major depressive disorder and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. The cognitive dysfunction, behavioural abnormalities and neuropsychological burden associated with these conditions is significantly debilitating for patients, and there is a substantial unmet medical need for new and improved treatments.

In this interview, CEO Dr Steven Gourlay discusses the company’s lead programme, what differentiates Xanamem and its mechanism of action from other approaches used to treat memory loss, and the upcoming Phase IIb study assessing Xanamem in Alzheimer’s disease.

< Previous
Next >

You may also be interested in these:

Healthcare

Actinogen Medical - executive interview

Healthcare

Actinogen: Edison Open House Healthcare 2022

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free